Trial · NCT03058289
Adverse events783
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 783
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Wound Infection | Infections and infestations | Monotherapy: (Cohort A1) | 1 | 6 | |
| other | Wound Infection | Infections and infestations | Monotherapy: (Cohort B1) | 0 | 4 | |
| other | Wound Infection | Infections and infestations | Monotherapy: (Cohort E-A) | 0 | 4 | |
| other | Wound Infection | Infections and infestations | Monotherapy: (Cohort E-C) | 0 | 21 | |
| other | Wound Infection | Infections and infestations | Monotherapy: (Cohort EC-2) | 0 | 20 | |
| other | Wound Infection | Infections and infestations | Monotherapy: (Cohort EC3) | 0 | 9 | |
| other | Wound Infection | Infections and infestations | INT230-6 Combined With Pembrolizumab (Cohorts DEC) | 0 | 8 | |
| other | Wound Infection | Infections and infestations | INT230-6 Combined With Pembrolizumab (Cohorts DEC2) | 0 | 22 | |
| other | Wound Infection | Infections and infestations | INT 230-6 Combined With Ipilimumab (Cohort FEC) | 0 | 18 | |
| other | Blister | Skin and subcutaneous tissue disorders | Monotherapy: (Cohort A1) | 1 | 6 | |
| other | Blister | Skin and subcutaneous tissue disorders | Monotherapy: (Cohort B1) | 0 | 4 | |
| other | Blister | Skin and subcutaneous tissue disorders | Monotherapy: (Cohort E-A) | 0 | 4 | |
| other | Blister | Skin and subcutaneous tissue disorders | Monotherapy: (Cohort E-C) | 0 | 21 | |
| other | Blister | Skin and subcutaneous tissue disorders | Monotherapy: (Cohort EC-2) | 0 | 20 | |
| other | Blister | Skin and subcutaneous tissue disorders | Monotherapy: (Cohort EC3) | 0 | 9 | |
| other | Blister | Skin and subcutaneous tissue disorders | INT230-6 Combined With Pembrolizumab (Cohorts DEC) | 0 | 8 | |
| other | Blister | Skin and subcutaneous tissue disorders | INT230-6 Combined With Pembrolizumab (Cohorts DEC2) | 0 | 22 | |
| other | Blister | Skin and subcutaneous tissue disorders | INT 230-6 Combined With Ipilimumab (Cohort FEC) | 0 | 18 | |
| other | Localized Tumor-Related Pain | General disorders | Monotherapy: (Cohort A1) | 2 | 6 | |
| other | Localized Tumor-Related Pain | General disorders | Monotherapy: (Cohort B1) | 2 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03058289/events